Isosorbide dinitrate

Revision as of 18:33, 30 January 2014 by Gerald Chi (talk | contribs) (Changed protection level for "Isosorbide dinitrate" ([Edit=Allow only autoconfirmed users] (expires 18:33, 13 February 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 18:33, 13 February 2014 (UTC))))
Jump to navigation Jump to search
Isosorbide dinitrate
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability10–90%, average 25%
MetabolismHepatic
Elimination half-life1 hour
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6H8N2O8
Molar mass236.136 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Isosorbide dinitrate (ISDN) is a nitrate used pharmacologically as a vasodilator, e.g. in angina pectoris but also for anal fissure, a condition which is known to involve decreased blood supply leading to poor healing. It is also used as a direct vasodilator to treat congestive heart failure.

Isosorbide dinitrate is sold under the brand names Isordil®[1] by Biovail, Cedocard® and Sorbitrate®. It is also a component of BiDil.

Uses

It is more useful in preventing angina attacks than reversing them once they have commenced. It may be given as a tablet for the treatment of an angina attack.

Advantages

Long acting nitrates can be more useful as they are generally more effective and stable in the short term.

Disadvantages

After long term use for treating chronic conditions, tolerance may develop in a patient reducing its effectiveness. The mechanisms of nitrate tolerance have been thoroughly investigated in the last 30 years and several hypotheses have been proposed. these include:

  1. Impaired biotransformation of ISDN to its active pinciple NO (or a NO-related species)
  2. Neurohormonal activation, causing sympathetic activation and release of vasoconstrictors such as endothelin and angiotensin II which counteract the vasodilation induced by ISDN
  3. Plasma volume expansion
  4. The oxidative stress hypothesis (proposed by Munzel et al in 1995).

Recent evidence suggests that the latter hypothesis might represent a unifying hypothesis, and an ISDN-induced inappropriate production of oxygen free radicals might induce a number of abnormalities which include the ones described above. Furthermore, studies have shown that nitrate tolerance is associated with vascular abnormalities which have the potential to worsen patients prognosis (Nakamura et al): these include endothelial and autonomic dysfunction (Gori et al). In the short run, ISDN can cause severe headaches, necessitating analgesic (very rarely up to morphine) administration for relief of pain as well as severe hypotension, and, in certain cases, bradycardia. This makes some physicians nervous and should prompt caution when starting nitrate administration.

Notes


Template:Antianginals (nitrates) Template:Preparations for treatment of wounds and ulcers

de:Isosorbiddinitrat th:ไอโซซอร์ไบด์ไดไนเตรต


Template:WikiDoc Sources